TrialClinical and translational science2022

Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.

Orestis Papasouliotis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.